

# Catrin Plumpton

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8479016/publications.pdf>

Version: 2024-02-01

30  
papers

992  
citations

516710

16  
h-index

501196

28  
g-index

31  
all docs

31  
docs citations

31  
times ranked

1529  
citing authors

#	ARTICLE	IF	CITATIONS
1	Supporting People With Type 2 Diabetes in the Effective Use of Their Medicine Through Mobile Health Technology Integrated With Clinical Care to Reduce Cardiovascular Risk: Protocol for an Effectiveness and Cost-effectiveness Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2022, 11, e32918.	1.0	1
2	Linear mixed models to handle missing at random data in trial-based economic evaluations. <i>Health Economics (United Kingdom)</i> , 2022, 31, 1276-1287.	1.7	27
3	The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. <i>Lancet, The</i> , 2021, 397, 1363-1374.	13.7	93
4	The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. <i>Lancet, The</i> , 2021, 397, 1375-1386.	13.7	104
5	Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs. <i>Health Technology Assessment</i> , 2021, 25, 1-134.	2.8	11
6	Study protocol for a pragmatic randomised controlled trial comparing the effectiveness and cost-effectiveness of levetiracetam and zonisamide versus standard treatments for epilepsy: a comparison of standard and new antiepileptic drugs (SANAD-II). <i>BMJ Open</i> , 2020, 10, e040635.	1.9	6
7	Reply. <i>Ophthalmology</i> , 2019, 126, e24-e25.	5.2	0
8	Patient-Focused Drug Development Methods for Benefit-Risk Assessments: A Case Study Using a Discrete Choice Experiment for Antiepileptic Drugs. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 672-683.	4.7	20
9	Attitudes towards epilepsy in the UK population: Results from a 2018 national survey. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2019, 65, 12-19.	2.0	26
10	Cost-Effectiveness of Panel Tests for Multiple Pharmacogenes Associated With Adverse Drug Reactions: An Evaluation Framework. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1429-1438.	4.7	25
11	Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT. <i>Health Technology Assessment</i> , 2019, 23, 1-140.	2.8	18
12	Rare disease prevention and treatment: the need for a level playing field. <i>Pharmacogenomics</i> , 2018, 19, 243-247.	1.3	3
13	Societal Preferences for Funding Orphan Drugs in the United Kingdom: An Application of Person Trade-Off and Discrete Choice Experiment Methods. <i>Value in Health</i> , 2018, 21, 538-546.	0.3	30
14	PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer. <i>Health Technology Assessment</i> , 2018, 22, 1-114.	2.8	82
15	The cancer care experiences of gay, lesbian and bisexual patients: A secondary analysis of data from the UK Cancer Patient Experience Survey. <i>European Journal of Cancer Care</i> , 2017, 26, e12670.	1.5	40
16	Cost-effectiveness of HLA-B*15:02 screening in Malaysia. <i>British Journal of Dermatology</i> , 2017, 177, 904-905.	1.5	5
17	Cost-Effectiveness of Pediatric Central Venous Catheters in the UK: A Secondary Publication from the CATCH Clinical Trial. <i>Frontiers in Pharmacology</i> , 2017, 8, 644.	3.5	5
18	Renal transplant patients' preference for the supply and delivery of immunosuppressants in Wales: a discrete choice experiment. <i>BMC Nephrology</i> , 2017, 18, 305.	1.8	2

#	ARTICLE	IF	CITATIONS
19	Multiple imputation of multiple multi-item scales when a full imputation model is infeasible. <i>BMC Research Notes</i> , 2016, 9, 45.	1.4	47
20	Conducting Economic Evaluations Alongside Randomised Trials: Current Methodological Issues and Novel Approaches. <i>Pharmacoeconomics</i> , 2016, 34, 447-461.	3.3	30
21	Pharmacogenetic testing prior to carbamazepine treatment of epilepsy: patients' and physicians' preferences for testing and service delivery. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1149-1159.	2.4	28
22	Economic evaluation of a behavior-modifying intervention to enhance antiepileptic drug adherence. <i>Epilepsy and Behavior</i> , 2015, 45, 180-186.	1.7	12
23	Adherence of patients to long-term medication: a cross-sectional study of antihypertensive regimens in Austria. <i>Wiener Klinische Wochenschrift</i> , 2015, 127, 379-384.	1.9	9
24	Predictors of Self-Reported Adherence to Antihypertensive Medicines: A Multinational, Cross-Sectional Survey. <i>Value in Health</i> , 2015, 18, 206-216.	0.3	58
25	Cost-effectiveness of screening for HLA-A*31:01 prior to initiation of carbamazepine in epilepsy. <i>Epilepsia</i> , 2015, 56, 556-563.	5.1	59
26	Investigating preferences for support with life after stroke: a discrete choice experiment. <i>BMC Health Services Research</i> , 2014, 14, 63.	2.2	18
27	Semi-supervised ensemble update strategies for on-line classification of fMRI data. <i>Pattern Recognition Letters</i> , 2014, 37, 172-177.	4.2	5
28	New advice on switching antiepileptic drugs might be a false economy. <i>BMJ, The</i> , 2013, 347, f7471-f7471.	6.0	1
29	Naive random subspace ensemble with linear classifiers for real-time classification of fMRI data. <i>Pattern Recognition</i> , 2012, 45, 2101-2108.	8.1	36
30	Random Subspace Ensembles for fMRI Classification. <i>IEEE Transactions on Medical Imaging</i> , 2010, 29, 531-542.	8.9	191